Nicolás A. Giraldo

AstraZeneca (United States) — United States

Medicine · Health Sciences

27h-index10.3kcitations149works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(85), Renal cell carcinoma treatment(44), Immunotherapy and Immune Responses(29), Immune Cell Function and Interaction(24), Renal and related cancers(20)

Publications149 total

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
2025Open Access
Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
2025Open Access
supplementary legend1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
2025Open Access
Supplementary Data1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
2025Open Access
An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release
Journal for ImmunoTherapy of Cancer·2025Open Access
Abstract 4303: AZD2284: A novel, alpha-particle emitting radioconjugate targeting STEAP2 in metastatic castration-resistant prostate cancer
Cancer Research·2025
Abstract 1158: Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer
Cancer Research·2025
Figure 1 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024Open Access
Figure 4 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024Open Access
Figure 6 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024Open Access
Figure 3 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024Open Access
Supplementary Data1 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024Open Access
Figure 2 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024Open Access
Data from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024Open Access
Figure 5 from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024Open Access
Efectos de la sentadilla profunda y media sentadilla sobre la potencia muscular en ciclistas de pista
Retos·2024Open Access
1073 AZD5863, a CLDN18.2 and CD3 binding T-cell engager, establishes a multi-faceted antitumour immune response and combines effectively with chemo-immunotherapy regimens
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
Clinical Cancer Research·2024· 27 citedOpen Access
CLDN18/CLDN18.2 IHC assay comparison (SP455, 43-14A, EPR19202) and co-prevalence expression with other biomarkers in gastric carcinoma.
Journal of Clinical Oncology·2024· 3 cited
235 Preclinical evaluation and anti-tumor activity of AZD6422, a CLDN18.2 targeting armored CAR-T for gastric, esophageal and pancreatic cancers
Regular and Young Investigator Award Abstracts·2023Open Access
page 1 of 8Next →

Frequent Co-authors

Catherine Sautès‐Fridman(26), Wolf H. Fridman(26), Étienne Becht(20), Aurélien de Reyniès(10), Yann Vano(10), Janis M. Taube(10), Laetitia Lacroix(9), Florent Petitprez(9), Marie‐Caroline Dieu‐Nosjean(8), Stéphane Oudard(7), Tricia R. Cottrell(7), Sneha Berry(7), Bénédicte Buttard(6), Pierre Laurent‐Puig(6), Claire Germain(6), Benjamin Green(6), Janick Sèlves(5), Robert A. Anders(5), Julie E. Stein(5), Elizabeth L. Engle(5)